share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4：持股变动声明-高管 Watanabe Todd Franklin
美股SEC公告 ·  12/04 05:22

Moomoo AI 已提取核心信息

Watanabe Todd Franklin completed a series of transactions involving Arcutis Biotherapeutics common stock. On 05/31/2024, he acquired 4,000 shares at $1.692 per share. Subsequently, on 11/30/2024, he purchased an additional 2,038 shares at $7.106 per share. The total number of shares acquired in these transactions was 6,038.Following these transactions, Watanabe's direct ownership of Arcutis Biotherapeutics shares increased to 838,430. The transactions were conducted as open market or private purchases. Additionally, Watanabe holds 231,140 shares indirectly through trusts and an LLC.These transactions reflect Watanabe's continued investment in Arcutis Biotherapeutics, with the latest acquisition completed on 11/30/2024. The transactions are now finalized, with no shares disposed of during this period.
Watanabe Todd Franklin completed a series of transactions involving Arcutis Biotherapeutics common stock. On 05/31/2024, he acquired 4,000 shares at $1.692 per share. Subsequently, on 11/30/2024, he purchased an additional 2,038 shares at $7.106 per share. The total number of shares acquired in these transactions was 6,038.Following these transactions, Watanabe's direct ownership of Arcutis Biotherapeutics shares increased to 838,430. The transactions were conducted as open market or private purchases. Additionally, Watanabe holds 231,140 shares indirectly through trusts and an LLC.These transactions reflect Watanabe's continued investment in Arcutis Biotherapeutics, with the latest acquisition completed on 11/30/2024. The transactions are now finalized, with no shares disposed of during this period.
渡边托德·富兰克林完成了一系列涉及Arcutis Biotherapeutics普通股的交易。2024年5月31日，他以每股1.692美元的价格收购了4,000股股票。随后，他在2024年11月30日以每股7.106美元的价格又购买了2,038股股票。在这些交易中收购的股份总数为6,038股。这些交易之后，渡边对Arcutis Biotherapeutics股票的直接所有权增加到838,430股。这些交易以公开市场或私人购买的形式进行。此外，渡边通过信托和有限责任公司间接持有231,140股股票。这些交易反映了渡边对Arcutis Biotherapeutics的持续投资，最新的收购于2024年11月30日完成。交易现已完成，在此期间没有出售任何股份。
渡边托德·富兰克林完成了一系列涉及Arcutis Biotherapeutics普通股的交易。2024年5月31日，他以每股1.692美元的价格收购了4,000股股票。随后，他在2024年11月30日以每股7.106美元的价格又购买了2,038股股票。在这些交易中收购的股份总数为6,038股。这些交易之后，渡边对Arcutis Biotherapeutics股票的直接所有权增加到838,430股。这些交易以公开市场或私人购买的形式进行。此外，渡边通过信托和有限责任公司间接持有231,140股股票。这些交易反映了渡边对Arcutis Biotherapeutics的持续投资，最新的收购于2024年11月30日完成。交易现已完成，在此期间没有出售任何股份。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间